<DOC>
	<DOC>NCT01711762</DOC>
	<brief_summary>This open-label, non-randomized study will assess the absorption, metabolism, and excretion of radioactive-labeled [14C]-GDC-0973 in healthy male volunteers. Volunteers will receive a single dose of [14C]-GDC-0973.</brief_summary>
	<brief_title>A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Body mass index (BMI) between 18.5 and 29.9 kg/m2, inclusive No clinically significant findings from medical history, 12lead ECG, and vital signs and laboratory evaluations Negative test for selected drugs of abuse No infection with hepatitis B, hepatitis C, human immunodeficiency virus (HIV) Sterile or agree to use an adequate contraception method Historically able to produce a minimum of 1 bowel movement per day Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance unless approved by the Investigator History of stomach or intestinal surgery or resection (including a cholecystectomy) that would potentially alter absorption and/or excretion of orally administered drugs except that appendectomy and/or hernia repair will be allowed History of Gilbert's Syndrome History of diabetes mellitus and/or elevated fasting glucose at baseline History or presence of an abnormal ECG History of alcoholism or drug addiction within 1 year prior Checkin Participation in more than one other radiolabeled investigational study drug trial within 12 months prior to Checkin Exposure to significant radiation within 12 months prior to Checkin study drug occurred within 5 halflives or 30 days, whichever is longer, prior to Checkin Use of any tobaccocontaining or nicotinecontaining products within 6 months prior to Checkin Participation in any other investigational study drug or biologic agent trial in which receipt of an investigational study drug occurred within 5 halflives or 30 days, whichever is longer, prior to Checkin Use of any prescription medications/products within 14 days prior to Checkin</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>